Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Urine abnormality, Urine analysis, White blood cell count
Clinical narrative: URINALYSIS, COMPLETE; APPEARANCE CLOUDY; MCH 26.8; MCHC 31.0; ABSOLUTE MONOCYTES 151; ABSOLUTE EOSINOPHILS 718; CHOLESTEROL, TOTAL 225/ 228; LDL-CHOLESTEROL 136/ 133; NON HDL CHOLESTEROL 155/ 151; The initial case was missing the following minimum criteria: adverse event. Upon receipt of follow-up information on 21Feb2024, this case now contains all required information to be considered valid.  This is a spontaneous report received from a Consumer or other non HCP.  An 81-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 03Oct2022 as dose 5 (booster), single (Lot number: G119693) at the age of 80 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension", start date: 1998 (ongoing), notes: high blood pressure cardiac; "Acid reflux", start date: 2003 (ongoing); "Asthma" (ongoing), notes: Onset Date: 1990's; "high cholesterol" (unspecified if ongoing). Concomitant medication(s) included: AMLODIPINE oral taken for hypertension (ongoing); LIVALO oral taken for blood cholesterol increased, start date: 2020 (ongoing); LOSARTAN oral taken for hypertension (ongoing); PANTOPRAZOLE oral taken for gastrooesophageal reflux disease (ongoing); ADVAIR resp inhalation taken for asthma (ongoing); PROTONIX [OMEPRAZOLE] oral taken for gastrooesophageal reflux disease (ongoing); PLAVIX (ongoing). Vaccination history included: BNT162b2 (DOSE 1, Administration time: around 14:00, Anatomical location: Upper left arm, Route of administration: Intramuscular, Batch/Lot number: Maybe Eng202), administration date: 26Feb2021, when the patient was 78-year-old, for COVID-19 Immunization; BNT162b2 (DOSE 2, Administration time: 14:00, Anatomical location: Upper left arm, Route of administration: Intramuscular, Batch/Lot number: ER8730), administration date: 26Mar2021, when the patient was 78-year-old, for COVID-19 Immunization; BNT162b2 (DOSE 3, Anatomical location: Upper left arm, Route of administration: Intramuscular, Batch/Lot number: 301458A), administration date: 27Sep2021, when the patient was 79-year-old, for COVID-19 Immunization; BNT162b2 (DOSE 4, Batch/Lot number: FM9893), administration date: 11Apr2022, when the patient was 79-year-old, for COVID-19 Immunization. The following information was reported: EOSINOPHIL COUNT INCREASED (non-serious) with onset 11Jan2023, outcome "unknown", described as "ABSOLUTE EOSINOPHILS 718"; MONOCYTE COUNT DECREASED (non-serious) with onset 11Jan2023, outcome "unknown", described as "ABSOLUTE MONOCYTES 151"; BLOOD CHOLESTEROL INCREASED (non-serious) with onset 11Jan2023, outcome "unknown", described as "CHOLESTEROL, TOTAL 225/ 228"; LOW DENSITY LIPOPROTEIN INCREASED (non-serious) with onset 11Jan2023, outcome "unknown", described as "LDL-CHOLESTEROL 136/ 133"; MEAN CELL HAEMOGLOBIN DECREASED (non-serious) with onset 11Jan2023, outcome "unknown", described as "MCH 26.8"; MEAN CELL HAEMOGLOBIN CONCENTRATION DECREASED (non-serious) with onset 11Jan2023, outcome "unknown", described as "MCHC 31.0"; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL INCREASED (non-serious) with onset 11Jan2023, outcome "unknown", described as "NON HDL CHOLESTEROL 155/ 151"; URINE ABNORMALITY (non-serious) with onset 07Jul2023, outcome "unknown", described as "URINALYSIS, COMPLETE; APPEARANCE CLOUDY". Relevant laboratory tests and procedures are available in the appropriate section.